With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
Both manufacturing facilities are based out of Benguluru, India
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
63-year old woman gets rare Transcatheter Tricuspid Valve Replacement (TTVR)
TMA will leverage Syntegra's synthetic data engine to accelerate the building of predictive diagnostic algorithms
Subscribe To Our Newsletter & Stay Updated
